Last updated: August 8, 2026
Seqirus is one of the largest influenza-vaccine manufacturers globally and the vaccines division of CSL Limited. Its position rests on a broad seasonal influenza portfolio, cell-based manufacturing, the FLUAD adjuvanted vaccine, government pandemic-preparedness contracts and global supply scale. The company competes primarily with Sanofi, GSK, AstraZeneca and emerging mRNA developers.
Seqirus has limited conventional small-molecule patent exposure because its core products are biologic vaccines rather than orally administered drugs. Its strongest barriers are manufacturing know-how, regulatory approvals, adjuvant technology, production capacity, procurement relationships and the cost of developing an alternative vaccine platform.
What is Seqirus and which vaccines does it sell?
Seqirus was created in 2015 when CSL acquired Novartis' influenza vaccine business. It operates within CSL's CSL Vifor, CSL Behring and Seqirus business structure, with influenza vaccines as its principal commercial focus.[1]
Seqirus product portfolio
| Product |
Active platform |
Principal market or use |
Key commercial attribute |
| FLUAD |
Egg-based, MF59-adjuvanted influenza vaccine |
Adults aged 65 and older |
Enhanced immune response in older adults |
| FLUCELVAX |
Cell-based influenza vaccine |
Seasonal influenza vaccination |
Avoids egg-adapted production strains |
| AFLURIA |
Egg-based influenza vaccine |
Seasonal influenza vaccination |
Broad age and presentation coverage |
| Pandemic influenza products |
Cell-based and other vaccine technologies |
Government preparedness and outbreak response |
Contract-driven and strategically important |
The U.S. product portfolio has shifted from quadrivalent to trivalent seasonal influenza vaccines following the removal of influenza B/Yamagata from vaccine composition recommendations. FDA approved trivalent versions of FLUAD, FLUCELVAX and AFLURIA for the 2024-2025 season.[2]
How large is Seqirus and what is its market position?
Seqirus is one of the largest influenza vaccine suppliers in the world and CSL's second-largest operating business after CSL Behring. CSL reported Seqirus revenue of approximately $2.1 billion for fiscal 2024, with performance influenced by seasonal vaccine demand, pricing, product mix and government contracts.[1]
The company has a stronger global influenza position than most biotechnology companies because it sells across the United States, Europe, Australia and other international markets. Its manufacturing network includes facilities in the United States, the United Kingdom, Australia and Germany.
Competitive position by category
| Category |
Seqirus position |
Leading competitors |
| Older-adult influenza vaccines |
Strong through FLUAD |
Sanofi, GSK |
| Cell-based influenza vaccines |
Strong, with FLUCELVAX |
Sanofi and emerging platform developers |
| Egg-based influenza vaccines |
Established |
Sanofi, GSK, Abbott |
| Nasal influenza vaccines |
Limited relative position |
AstraZeneca's FluMist |
| mRNA influenza vaccines |
Development-stage exposure rather than commercial leadership |
Moderna, Pfizer, BioNTech |
| Pandemic preparedness |
Strong government and manufacturing position |
Sanofi, GSK, AstraZeneca, Moderna |
CSL identifies Seqirus as the world's second-largest influenza vaccine company by revenue, behind Sanofi.[1] The competitive ranking can change by season because vaccine contracts, strain selection, public-health purchasing and production yields vary annually.
What are Seqirus' main commercial strengths?
FLUAD and the older-adult segment
FLUAD is Seqirus' principal differentiated seasonal influenza product. It uses MF59, an oil-in-water adjuvant based on squalene, to improve immune response in older adults. The product targets a population with higher hospitalization and mortality risk from influenza.
The older-adult segment has strategic value because it supports premium pricing and reduces direct comparability with standard-dose influenza vaccines. Sanofi's Fluzone High-Dose and GSK's Fluad-related offerings create substantial competition, but adjuvanted and enhanced influenza vaccines generally have stronger product differentiation than standard-dose vaccines.
Cell-based manufacturing
FLUCELVAX is produced using cell-based technology rather than conventional egg-based production. The platform can reduce the risk that egg adaptation changes the antigenic characteristics of the vaccine strain during production. It also provides an alternative to the global egg-supply chain.
Cell-based manufacturing has higher technical and capital requirements than standard egg production. The barriers include validated cell banks, bioreactor capacity, production controls, release testing, regulatory comparability and specialized quality systems.
Government relationships
Seqirus has long-standing relationships with the U.S. Biomedical Advanced Research and Development Authority, the U.S. Department of Health and Human Services and other public procurement agencies. These relationships support pandemic influenza preparedness, stockpiling, development funding and manufacturing-capacity commitments.
Government contracts can provide non-seasonal revenue and strategic utilization of manufacturing assets. They also impose delivery obligations, pricing constraints and regulatory milestones.
Geographic manufacturing scale
Seqirus operates production and distribution infrastructure across multiple regions. Geographic diversification reduces dependence on a single manufacturing site and improves access to national procurement systems. It also supports supply to countries that use different regulatory standards, procurement cycles and vaccine compositions.
What patents protect Seqirus influenza vaccines?
Seqirus' commercial protection comes from a combination of patents, regulatory approvals, manufacturing know-how, trade secrets, trademarks and government contracts. The most important technical categories are:
- MF59 adjuvant compositions and uses.
- Cell-based influenza production processes.
- Cell lines, culture conditions and virus propagation methods.
- Vaccine purification and inactivation processes.
- Formulation, stabilization and presentation technologies.
- Strain-specific manufacturing and analytical methods.
Are FLUAD, FLUCELVAX and AFLURIA listed in the Orange Book?
No. The FDA Orange Book primarily covers approved small-molecule drug products and associated listed patents. Seasonal influenza vaccines are biological products and are generally not represented in the Orange Book in the same manner as conventional abbreviated new drug application products.[3]
This distinction matters for generic-entry analysis. A competitor does not normally challenge a Seqirus influenza vaccine through a conventional Orange Book Paragraph IV filing. It would pursue the applicable biologic license application pathway, including a stand-alone biologics license application or, where legally available, a biosimilar pathway.
What formulations are protected by Seqirus' patent estate?
The principal formulation protections relate to:
- MF59 oil-in-water adjuvant composition.
- Squalene-based emulsion parameters.
- Surfactant and solvent combinations.
- Antigen-adjuvant combinations.
- Stability and storage conditions.
- Multidose and prefilled-syringe presentations.
Many foundational MF59 patent families were filed decades ago. As a result, the commercial durability of FLUAD is less dependent on one unexpired composition patent than on manufacturing controls, regulatory data, brand recognition, quality records and procurement access.
The strongest current IP may sit in process patents and confidential know-how rather than in publicly visible product claims. Cell-culture media, cell-bank management, virus growth, purification and scale-up conditions can be difficult to replicate even when broad patent claims have expired.
When does Seqirus lose exclusivity?
Seqirus does not face one universal loss-of-exclusivity date across its influenza portfolio. Protection differs by product, jurisdiction and technology.
| Protection type |
Typical relevance to Seqirus |
Commercial impact |
| Foundational adjuvant patents |
MF59 and related compositions |
Many early families may be expired or near expiration |
| Process patents |
Cell culture, purification and formulation |
Can remain relevant if claims are narrow and production-specific |
| Regulatory exclusivity |
Biologic approval and product-specific regulatory protection |
Limits certain follow-on filings for defined periods |
| Trade secrets |
Cell banks, manufacturing parameters and analytical controls |
Potentially indefinite if maintained |
| Trademarks |
FLUAD, FLUCELVAX and AFLURIA |
Protect brand identity, not the vaccine molecule |
| Procurement contracts |
Government supply commitments |
Create commercial access and volume advantages |
Influenza vaccines also change composition each season. A competitor must maintain annual strain updates, clinical and analytical support, regulatory manufacturing compliance and reliable supply. This makes market entry more operationally demanding than simply waiting for a single patent to expire.
Are there Paragraph IV challenges or biosimilar risks to Seqirus?
Paragraph IV risk
Paragraph IV litigation is not the standard route for challenging Seqirus' seasonal vaccines because the products are biologics rather than Orange Book-listed small molecules. No conventional Paragraph IV generic challenge is central to the current Seqirus influenza portfolio.
Competition instead arises from:
- New biologics licensed through a stand-alone BLA.
- Biosimilar or interchangeable-biologic applications where legally and scientifically applicable.
- Alternative influenza platforms, including recombinant, cell-based, live attenuated and mRNA vaccines.
- Government tenders and public-health procurement competition.
Biosimilar risk
Biosimilar risk is limited for seasonal influenza vaccines. Vaccine products are complex, strain-dependent biological systems, and commercial substitution is not governed solely by molecular similarity. Each competitor must demonstrate product quality, immunogenicity, safety, manufacturing consistency and regulatory compliance.
The more immediate risk is platform substitution rather than classic biosimilar erosion. Recombinant and mRNA vaccines could compete with egg-based and cell-based products if they demonstrate superior effectiveness, faster strain updating, improved production economics or stronger pandemic utility.
What is the FDA regulatory status of Seqirus vaccines?
Seqirus' principal U.S. influenza products are licensed biological products. The FDA has approved the company's seasonal products for defined age groups and presentations, with updates required as influenza strains and labeling change.
Recent regulatory milestones
| Milestone |
Approximate date |
Significance |
| FLUAD U.S. approval |
2015 |
Expanded adjuvanted influenza-vaccine access for older adults |
| FLUCELVAX U.S. approval |
2016 |
Established a cell-based influenza platform in the U.S. |
| FLUAD QUADRIVALENT approval |
2020 |
Expanded seasonal strain coverage |
| FLUCELVAX age expansion |
2021 |
Broadened eligible population |
| Trivalent 2024-2025 products |
2024 |
Reflected removal of B/Yamagata from seasonal vaccines |
FDA approval is not permanent commercial protection. Seqirus must continue to meet annual manufacturing, strain-composition, pharmacovigilance and lot-release requirements.
What patent litigation affects Seqirus?
Publicly visible litigation risk for Seqirus is lower than for branded small-molecule companies with large Orange Book portfolios. The principal legal exposure is more likely to arise from:
- Manufacturing patent disputes.
- Trade-secret claims involving cell culture or production methods.
- Contract disputes with government or commercial purchasers.
- Product liability and vaccine-injury litigation.
- Trademark disputes.
- Regulatory challenges involving approval, labeling or procurement.
The absence of a major Orange Book litigation campaign does not mean that Seqirus has no IP risk. Manufacturing know-how is difficult to enforce through patent litigation if claims are narrow, but trade-secret misappropriation can create substantial liability where confidential production information is involved.
Which companies are challenging Seqirus?
Sanofi
Sanofi is Seqirus' most direct global competitor. Its influenza portfolio includes Fluzone, Fluzone High-Dose and other products targeting older adults and general seasonal vaccination. Sanofi has greater scale in some public-health markets and a strong U.S. commercial infrastructure.
GSK
GSK competes through Fluarix and enhanced influenza products. Its strength is concentrated in vaccine commercialization, physician relationships and public-sector procurement.
AstraZeneca
AstraZeneca's FluMist is a live attenuated nasal vaccine. Its needle-free administration gives it a distinct position, especially in pediatric and mass-vaccination settings.
Moderna and other mRNA developers
Moderna, Pfizer and other developers have pursued mRNA influenza programs. These companies could challenge Seqirus if mRNA products improve strain-matching speed, manufacturing flexibility or efficacy. Their risk remains development and regulatory execution rather than established commercial substitution.
How does Seqirus compare with Sanofi and GSK?
| Factor |
Seqirus |
Sanofi |
GSK |
| Core advantage |
Cell-based production and FLUAD |
Scale, high-dose products and global reach |
Vaccine portfolio and commercial scale |
| Older-adult segment |
Strong |
Strong |
Strong |
| Cell-based influenza |
Commercial leadership through FLUCELVAX |
Competitive presence |
Less central to market identity |
| Manufacturing flexibility |
Strong across egg and cell-based systems |
Broad |
Broad |
| Pandemic preparedness |
Strong government relationship |
Strong |
Strong |
| Patent dependence |
Moderate, with significant know-how |
Moderate |
Moderate |
| Generic substitution risk |
Low in conventional sense |
Low |
Low |
| Platform disruption risk |
Moderate |
Moderate |
Moderate |
Seqirus' differentiation is clearest where cell-based production and adjuvanted vaccination matter. Sanofi and GSK have greater scale and deep commercial relationships, while Seqirus has a more focused influenza identity.
What revenue exposure does Seqirus create for CSL?
Seqirus contributes approximately one-seventh of CSL's consolidated revenue, based on CSL's fiscal 2024 reported figures.[1] The business is seasonal and exposed to several variables:
- Annual vaccination rates.
- Timing and severity of influenza seasons.
- Government procurement volumes.
- Product mix between standard, cell-based and adjuvanted vaccines.
- Manufacturing yields.
- Strain changes.
- Public-health recommendations.
- Competitive pricing.
Its revenue is less predictable than chronic biologic therapies because demand is concentrated in a limited annual vaccination window. The business also requires substantial inventory planning before the influenza season, creating working-capital and supply-chain exposure.
What strategic opportunities does Seqirus have?
Expand differentiated influenza products
The strongest near-term opportunity is growth in enhanced influenza vaccines for older adults. Population aging supports this segment, but reimbursement, procurement policy and comparative-effectiveness evidence will determine pricing power.
Use cell-based capacity for pandemic response
Cell-based manufacturing can support faster adaptation than traditional egg systems in some circumstances. Expanded government contracts could improve facility utilization and offset the seasonal nature of the business.
Develop combination and next-generation vaccines
Combination respiratory vaccines, broader-spectrum influenza vaccines and improved-dose formulations could increase value per vaccination. These products would also generate new regulatory and patent opportunities.
Build evidence around real-world outcomes
Hospitalization reduction, mortality reduction and comparative effectiveness against high-dose, recombinant and standard vaccines can influence payer and government purchasing decisions. Clinical and health-economic evidence may provide greater commercial value than additional narrow patent claims.
What generic launch scenarios exist for Seqirus vaccines?
A conventional generic launch is unlikely to be the principal threat. The more realistic scenarios are:
- A rival standard-dose vaccine wins government contracts through lower pricing.
- A competing adjuvanted or high-dose product captures older-adult demand.
- A recombinant vaccine reduces reliance on egg and cell-based platforms.
- An mRNA vaccine gains approval with faster strain-updating capability.
- A competitor achieves superior effectiveness in a particular season.
- Public-health agencies shift procurement toward a different platform.
The main entry barriers are manufacturing validation, annual strain updates, clinical evidence, quality systems, supply reliability and procurement relationships.
How strong is Seqirus' patent estate?
Seqirus has a strategically valuable but uneven patent estate. Its strength is highest in platform and process know-how, not in a single long-dated product patent.
Patent-strength assessment
| Dimension |
Assessment |
| Product composition patents |
Moderate to weak for older foundational technologies |
| Adjuvant technology |
Historically important, but foundational claims face age-related expiry |
| Cell-based production |
Stronger where process claims and know-how remain proprietary |
| Trade secrets |
Potentially strong if production information is controlled |
| Regulatory protection |
Important but product- and jurisdiction-specific |
| Trademark protection |
Strong for established brands |
| Manufacturing scale |
High practical barrier to entry |
| Litigation leverage |
Lower than major small-molecule portfolios |
Geographic protection varies by patent family and national prosecution history. U.S., European, Australian and other national rights must be assessed separately. A patent family that is expired or abandoned in one jurisdiction may remain active in another, although the commercial importance depends on local vaccine procurement and manufacturing capacity.
Key Takeaways
- Seqirus is a leading global influenza-vaccine company and a major CSL revenue contributor.
- FLUAD gives Seqirus a differentiated position in the older-adult market.
- FLUCELVAX provides commercial and strategic value through cell-based manufacturing.
- Seqirus' principal barriers are manufacturing scale, regulatory expertise, government contracts and trade secrets.
- The Orange Book and conventional Paragraph IV framework have limited relevance to its vaccine portfolio.
- Biosimilar risk is lower than platform-substitution risk from recombinant and mRNA influenza vaccines.
- Sanofi and GSK are the closest commercial competitors; AstraZeneca is differentiated through nasal delivery.
- Revenue remains exposed to seasonal demand, procurement cycles, strain changes and vaccination rates.
- The patent estate is more valuable as a platform and process portfolio than as a set of long-lived composition patents.
- Future competitive pressure will depend on effectiveness, production speed, procurement economics and pandemic readiness.
FAQs About Seqirus Patent and Competitive Risk
Does Seqirus have an Orange Book patent listed for FLUAD?
No. FLUAD is a biologic influenza vaccine, and its protection is not generally represented through the conventional Orange Book patent-listing system used for small-molecule drugs.
Can a company launch a generic version of FLUCELVAX after patent expiration?
A conventional generic launch is not the expected pathway. A competitor would need to obtain the appropriate biologic approval and demonstrate manufacturing, quality, safety and immunogenicity requirements.
Is FLUAD protected by MF59 patents?
MF59 has been associated with patent protection covering squalene-based oil-in-water adjuvant compositions and uses. The commercial value of FLUAD also depends on manufacturing controls, regulatory records, branding and clinical evidence.
Which next-generation technology poses the greatest risk to Seqirus?
mRNA influenza vaccines pose the clearest platform-level risk if they demonstrate faster strain updating, strong effectiveness and competitive production economics. Recombinant vaccines also compete with egg-based and cell-based products.
Does CSL's ownership strengthen Seqirus' competitive position?
Yes. CSL provides capital, global manufacturing infrastructure, regulatory capabilities and access to public-sector relationships. That support helps Seqirus manage the high fixed costs and seasonal working-capital demands of influenza-vaccine production.
References
- CSL Limited. (2024). Annual report 2024. CSL Limited.
- U.S. Food and Drug Administration. (2024). Influenza virus vaccine products and approvals for the 2024-2025 season. FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
- CSL Seqirus. (2024). Influenza vaccines and product information. CSL Seqirus.
- U.S. Department of Health and Human Services. (2024). Biomedical Advanced Research and Development Authority contracting and pandemic influenza preparedness materials. HHS.
